Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Eve Burstein
BERN

Eve Burstein

Bernstein
Wall Street Analyst
★★★★☆
#326
on 13Foresight · ranked by our own returns
60%
Success Rate
+6.9%
Average Return
49 of 81 calls profitable · +5.0% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 60% of Eve Burstein's ratings turned a profit when each position was held for 1 year — averaging +6.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

29 Buy 27 Hold 0 Sell
Eve's Stock Coverage 14 ratings · 2026-11-06
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AVTR
Avantor
 Oct 19, 2026 HOLD Buy
+4.5% avg upside
27 analysts
$15.50
3.39% Downside
 -7.1% ·
ILMN
Illumina
 Oct 19, 2026 HOLD Buy
-10.0% avg upside
32 analysts
$215.00
8.80% Downside
 -19.0% ·
RVTY
Revvity
 Oct 19, 2026 HOLD Buy
-20.0% avg upside
25 analysts
$120.00
23.49% Downside
 +2.8% ·
TMO
Thermo Fisher
 Oct 19, 2026 HOLD Strong Buy
-5.2% avg upside
40 analysts
$575.00
17.55% Downside
 +3.9% ·
WAT
Waters
 Oct 19, 2026 BUY Strong Buy
-12.6% avg upside
31 analysts
$450.00
2.79% Downside
 +5.8% ·
NTRA
Natera
 Oct 19, 2026 BUY Strong Buy
-13.2% avg upside
28 analysts
$365.00
11.82% Downside
 -22.0% ·
GH
Guardant Health
 Oct 19, 2026 BUY Strong Buy
-3.1% avg upside
33 analysts
$210.00
17.40% Upside
 -4.4% ·
A
Agilent
 Oct 19, 2026 BUY Strong Buy
-8.1% avg upside
35 analysts
$180.00
2.98% Upside
 +2.9% ·
BIIB
Biogen
 Sep 25, 2026 BUY Strong Buy
+6.6% avg upside
53 analysts
$236.00
6.88% Downside
 +7.2% ·
REGN
Regeneron
 Sep 25, 2026 HOLD Strong Buy
-12.1% avg upside
60 analysts
$756.00
18.54% Downside
 +14.6% ·
IMVT
Immunovant
 Sep 25, 2026 HOLD Strong Buy
+38.4% avg upside
25 analysts
$37.00
26.78% Upside
 -14.7% ·
ROIV
Roivant Sciences
 Sep 25, 2026 BUY Strong Buy
+10.7% avg upside
19 analysts
$41.00
11.07% Upside
 +6.8% ·
PACB
Pacific Biosciences
 Aug 08, 2025 BUY Buy
+73.8% avg upside
14 analysts
$1.70
34.82% Downside
 -11.8% ·
DE:SRT3
Sartorius
 Jan 06, 2025 SELL Strong Buy
-0.2% avg upside
19 analysts
$194.00
33.54% Downside
 -14.5% ·
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Eve Burstein — Frequently Asked Questions
How accurate are Eve Burstein's stock ratings?
Based on the calls 13Foresight could measure, about 60% of Eve's ratings were profitable over a one-year hold, with an average return of +6.8% per rating, or +4.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Eve ranked on 13Foresight?
Eve Burstein is currently ranked #326 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Eve cover?
Eve most recently has ratings on AVTR, ILMN, RVTY, TMO, WAT, NTRA, GH, A, BIIB, REGN, IMVT, ROIV and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.